A running list of my sources:
Causes of Death:
World Health Organization. (2012). Causes of death. Retrieved July 28, 2016, from http://www.who.int/gho/mortality_burden_disease/causes_death/en/
Heart Disease:
Bitton, A., & Gaziano, T. (2010). The Framingham Heart Study’s Impact on Global Risk Assessment. Progress in Cardiovascular Diseases, 53(1), 68-78. doi:10.1016/j.pcad.2010.04.001 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904478/
Casula, M., Soranna, D., Catapano, A. L., & Corrao, G. (2013). Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials.Atherosclerosis Supplements, 14(2), 243-251. doi:10.1016/s1567-5688(13)70005-9 http://www.ncbi.nlm.nih.gov/pubmed/23958480
CDC. (2015). Conditions that increase risk for heart disease. Retrieved from http://www.cdc.gov/heartdisease/conditions.htm
Framingham Heart Study. (2016). Framingham Heart Study. Retrieved from http://www.framinghamheartstudy.org/index.php
High Blood Pressure:
Franco, O. H., Peeters, A., Bonneux, L., & De Laet, C. (2005). Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women: Life Course Analysis. Hypertension, 46(2), 280-286. doi:10.1161/01.hyp.0000173433.67426.9b. http://hyper.ahajournals.org/content/46/2/280.full
Omega-3:
Casula, M., Soranna, D., Catapano, A. L., & Corrao, G. (2013). Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials.Atherosclerosis Supplements, 14(2), 243-251. doi:10.1016/s1567-5688(13)70005-9 http://www.ncbi.nlm.nih.gov/pubmed/23958480